Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Addus HomeCare CorpADUS · Entity 4454 | Director | June 10, 2026 | June 11, 2026 |
| Axonics, Inc.AXNX · Entity 86004 | Director | November 15, 2024 | November 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Addus HomeCare Corp
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,649 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 1,449 · Balance 4,649 F1: Restricted shares granted to non-employee directors that will vest in full on June 10, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares granted to non-employee directors that will vest in full on June 10, 2027.
Axonics, Inc.
Report date November 15, 2024 · Filed November 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 1
1 source rowRow 1 · 2024-11-15 · Disposition to issuer · Disposed 6,600 · Balance 0 F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.70 · Expires 2031-07-15 | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration").
F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 20:32 UTC | Addus HomeCare Corp ADUS · Entity 4454 | GrantCommon Stock | 1,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-020321 · rdgdoc.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,649 F1 · shares: Restricted shares granted to non-employee directors that will vest in full on June 10, 2027. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:30 UTC | Addus HomeCare Corp ADUS · Entity 4454 | SaleCommon Stock | 250 | $93.00 | $23,250.00 |
DisclosureSEC source: 0001437749-26-018260 · rdgdoc.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:30 UTC | Addus HomeCare Corp ADUS · Entity 4454 | SaleCommon Stock | 250 | $93.00 | $23,250.00 |
DisclosureSEC source: 0001437749-26-018105 · rdgdoc.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,450 Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:30 UTC | Addus HomeCare Corp ADUS · Entity 4454 | SaleCommon Stock | 100 | $115.50 | $11,550.00 |
DisclosureSEC source: 0001437749-25-038024 · rdgdoc.xml · nonDerivative · entry 2 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,700 Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:30 UTC | Addus HomeCare Corp ADUS · Entity 4454 | SaleCommon Stock | 50 | $114.55 | $5,727.50 |
DisclosureSEC source: 0001437749-25-038024 · rdgdoc.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,800 Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:30 UTC | Addus HomeCare Corp ADUS · Entity 4454 | SaleCommon Stock | 166 | $112.78 | $18,721.48 |
DisclosureSEC source: 0001437749-25-037154 · rdgdoc.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,850 Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 20:30 UTC | Addus HomeCare Corp ADUS · Entity 4454 | SaleCommon Stock | 522 | $109.00 | $56,898.00 |
DisclosureSEC source: 0001437749-25-025944 · rdgdoc.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,016 Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:30 UTC | Addus HomeCare Corp ADUS · Entity 4454 | GrantCommon Stock | 1,172 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-088540 · ownership.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,538 F1 · shares: Restricted shares granted to non-employee directors that will vest in full on June 18, 2026. Read SEC document |
| November 15, 2024 Filed Nov 15, 2024 08:59 UTC | Axonics, Inc. AXNX · Entity 86004 | Disposition to issuerStock Options (Right to buy) · Derivative | 10,000 | $11.30 Strike: $59.70 | $113,000.00 |
DisclosureSEC source: 0001562180-24-007706 · primarydocument.xml · derivative · entry 2 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2031-07-15 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions. Read SEC document |
| November 15, 2024 Filed Nov 15, 2024 08:59 UTC | Axonics, Inc. AXNX · Entity 86004 | Disposition to issuerCommon Stock | 6,600 | $71.00 | $468,600.00 |
DisclosureSEC source: 0001562180-24-007706 · primarydocument.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"). F1 · price: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"). Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 20:30 UTC | Addus HomeCare Corp ADUS · Entity 4454 | SaleCommon Stock | 500 | $127.50 | $63,750.00 |
DisclosureSEC source: 0000950170-24-105530 · ownership.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,366 Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 20:30 UTC | Addus HomeCare Corp ADUS · Entity 4454 | SaleCommon Stock | 500 | $130.03 | $65,015.00 |
DisclosureSEC source: 0000950170-24-104405 · ownership.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,866 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:05 UTC | Addus HomeCare Corp ADUS · Entity 4454 | GrantCommon Stock | 1,013 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-072985 · ownership.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,366 F1 · shares: Restricted shares granted to non-employee directors that will vest in full on June 12, 2025. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 20:22 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005535 · primarydocument.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,600 Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:59 UTC | Addus HomeCare Corp ADUS · Entity 4454 | GrantCommon Stock | 1,289 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037951 · doc4.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,353 F1 · shares: Restricted shares granted to non-employee directors that will vest in full on June 14, 2024. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 20:12 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 2,000 | $67.42 | $134,840.00 |
DisclosureSEC source: 0001562180-22-008326 · primarydocument.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 20:14 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-006267 · primarydocument.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 21:30 UTC | Addus HomeCare Corp ADUS · Entity 4454 | SaleCommon Stock | 1,100 | $95.00 | $104,500.00 |
DisclosureSEC source: 0001209191-22-046014 · doc4.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,064 Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:44 UTC | Addus HomeCare Corp ADUS · Entity 4454 | GrantCommon Stock | 1,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037916 · doc4.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,164 F1 · shares: Restricted shares granted to non-employee directors that will vest in full on June 15, 2023. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 21:22 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $59.70 | $0.00 |
DisclosureSEC source: 0001562180-21-005006 · primarydocument.xml · derivative · entry 2 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-15 F1 · shares: The option becomes exercisable in full on July 15, 2022, provided the reporting person remains in continuous service through such date. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 21:22 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-005006 · primarydocument.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:41 UTC | Addus HomeCare Corp ADUS · Entity 4454 | GrantCommon Stock | 1,304 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042051 · doc4.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,758 F1 · shares: Restricted shares granted to non-employee directors that will vest in full on June 16, 2022. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 20:24 UTC | Addus HomeCare Corp ADUS · Entity 4454 | GrantCommon Stock | 454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003228 · doc4.xml · nonDerivative · entry 1 Lopez Esteban · CIK 0001839999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454 F1 · shares: Restricted shares granted to non-employee directors that will vest in full on June 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.